ライフサイエンスコーパス: high-grade serous ovarian cancer

1 eatment planning and treatment monitoring of high-grade serous ovarian cancer.

2 ith better overall survival in patients with high-grade serous ovarian cancer.

3 patients with platinum-sensitive, recurrent, high-grade serous ovarian cancer.

4 mad7, and the TGF-beta signalling pathway in high-grade serous ovarian cancer.

5 r prognosis in patients with advanced stage, high-grade serous ovarian cancer.

6 mor deposits and ascites that resemble human high-grade serous ovarian cancer.

7 r patients with platinum-sensitive, relapsed high-grade serous ovarian cancer.

8 patients with platinum-sensitive, relapsed, high-grade serous ovarian cancer.

9 n (HR) repair, occur in approximately 20% of high grade serous ovarian cancers.

10 potential over clonal populations comprising high-grade serous ovarian cancers.

11 e prognostic biomarkers for endometrioid and high-grade serous ovarian cancers.

12 We performed phylogenetic analysis of high-grade serous ovarian cancers (68 samples from seven

13 High-grade serous ovarian cancers account for most ovari

14 in patients with sporadic platinum-resistant high-grade serous ovarian cancer and sporadic prostate c

15 ied and overexpressed in a subset of primary high-grade serous ovarian cancers and cell lines.

16 h gene, PAX8, is focally amplified in 16% of high-grade serous ovarian cancers and expressed at highe

17 gene is co-amplified with PIK3CA in 29.3% of high-grade serous ovarian cancers and its overexpression

18 ase 2 (beta) (CaMKK2) is highly expressed in high-grade serous ovarian cancer, and we investigated it

19 High-grade serous ovarian cancers are characterized by w

20 e, and the development of drug resistance in high-grade serous ovarian cancers are related to distinc

21 ed cell line series from three patients with high-grade serous ovarian cancer before and after develo

22 Among women with high-grade serous ovarian cancer, BRCA2 mutation, but no

23 BRCAPRO underestimated the risk for high-grade serous ovarian cancers but overestimated the

24 atients precedes the radiologic detection of high-grade serous ovarian cancer by at least 2 mo and th

25 imensional genomics and clinical data on 316 high-grade serous ovarian cancer cases that were made pu

26 cted decitabine sensitivity in low-grade and high-grade serous ovarian cancer cells.

27 hin 5'-TC dinucleotide motifs in early-stage high-grade serous ovarian cancer genomes, suggesting tha

28 Disseminated high-grade serous ovarian cancer (HGS-OvCa) is an aggres

29 In models of high-grade serous ovarian cancer (HGS-OVCa), CDK12 atten

30 drug resistance in ovarian and other cancers.High-grade serous ovarian cancers (HGS-OvCa) frequently

31 The lack of effective chemotherapies for high-grade serous ovarian cancers (HGS-OvCa) has motivat

32 ne BRCA1 or BRCA2 mutations in patients with high-grade serous ovarian cancer (HGSC) are associated w

33 Patients with high-grade serous ovarian cancer (HGSC) have experienced

34 High-grade serous ovarian cancer (HGSC) is among the mos

35 High-grade serous ovarian cancer (HGSC) is an aggressive

36 TE) is one of the progenitor populations for high-grade serous ovarian cancer (HGSC).

37 ) has been recognized as a site of origin of high-grade serous ovarian cancer (HGSC).

38 High-grade serous ovarian cancers (HGSCs) are characteri

39 High-grade serous ovarian cancers (HGSCs) are deadly mal

40 erum and tumor tissue from 158 patients with high-grade serous ovarian cancer (HGSOC) and 100 control

41 s and computed tomography (CT) phenotypes of high-grade serous ovarian cancer (HGSOC) and to evaluate

42 major clinical challenge in the treatment of high-grade serous ovarian cancer (HGSOC) is the developm

43 Early genetic events in the development of high-grade serous ovarian cancer (HGSOC) may define the

44 UBB is repressed in approximately 30% of high-grade serous ovarian cancer (HGSOC) patients and is

45 A cell line representative of human high-grade serous ovarian cancer (HGSOC) should not only

46 computed tomography (CT) imaging features of high-grade serous ovarian cancer (HGSOC), to assess thei

47 To determine early somatic changes in high-grade serous ovarian cancer (HGSOC), we performed w

48 e are no approved biomarkers for olaparib in high-grade serous ovarian cancer (HGSOC).

49 LR-high) groups, especially in patients with high-grade serous ovarian cancer (HGSOC).

50 ECs, OSECs), the debated cellular origins of high-grade serous ovarian cancers (HGSOCs) and in endome

51 High-grade serous ovarian cancer is an aggressive form o

52 High-grade serous ovarian cancer is the most common ovar

53 umour activity was also reported in sporadic high-grade serous ovarian cancer, non-small-cell lung ca

54 0-1 and histologically confirmed, relapsed, high-grade serous ovarian cancer or high-grade endometri

55 In high-grade serous ovarian cancer (OV), the bulk of genet

56 In matched samples from 11 high-grade serous ovarian cancer patients, we detected 2

57 1/BRCA2 genetic testing to all patients with high-grade serous ovarian cancer regardless of family hi

58 cancer cell line and as small as 9 Mb in two high-grade serous ovarian cancer samples using only 0.02

59 lications of BRCA status in the patient with high-grade serous ovarian cancer, the differences betwee

60 en proposed instead as the primary origin of high-grade serous ovarian cancer, the subtype causing 70

61 resent an exceptional case of a patient with high-grade serous ovarian cancer, treated with multiple

62 commonly used ovarian cancer cell lines and high-grade serous ovarian cancer tumour samples.

63 en evaluated multi-omics profiles of primary high-grade serous ovarian cancer tumours (N=357) to deli

64 and are evaluated as a diagnostic probe for high-grade serous ovarian cancer, typically diagnosed at

65 entify a stromal gene signature for advanced high-grade serous ovarian cancer using microdissected st

66 d with the development of drug resistance in high-grade serous ovarian cancer, were examined from pat

67 patients with platinum-sensitive, relapsed, high-grade serous ovarian cancer who had received two or

68 patients with platinum-sensitive, recurrent, high-grade serous ovarian cancer who had received up to

69 patients with platinum-sensitive, recurrent, high-grade serous ovarian cancer with or without BRCA1 o

70 as shown antitumor activity in patients with high-grade serous ovarian cancer with or without BRCA1 o

71 n performed meta-analysis on the results for high-grade serous ovarian cancer with the results from a